Literature DB >> 9467558

Characterization of a truncated progesterone receptor protein in breast tumors.

C Yeates1, S M Hunt, R L Balleine, C L Clarke.   

Abstract

The progesterone receptor (PR) mediates the actions of progesterone in the normal and malignant breast. PR is expressed as two proteins, PR B and PR A, which are expressed in normal progesterone target tissues and in breast cancers. A significant proportion of breast cancers contain, in addition, a smaller PR protein of molecular mass 78 kDa (PR78 kDa). The significance of PR78 kDa expression is unknown, and in particular, there are no data on whether PR78 kDa is able to bind ligand and therefore potentially exhibit transcriptional activity. If this smaller PR species exhibits similar differences in function as have been evidenced in vitro for PR A relative to PR B, it is possible that this PR species may be an important component in determination of progesterone response in breast cancer. The purpose of this study was to determine whether the PR78 kDa protein in breast tumors is able to bind ligand and to determine whether posttranscriptional mechanisms contribute to its formation in breast cancers. There was no evidence that PR78 kDa was derived from proteolytic activity of either PR B or PR A. Similarly, although exon-deleted PR transcripts were detected (which could, if translated, give rise to a PR protein similar in size to PR78 kDa), neither the abundance of such transcripts nor their relationship to levels of expressed PR78 kDa protein supported a role for exon deletion in formation of this truncated PR protein. PR78 kDa was not recognized by an antibody specific for PR B, indicating that, like PR A, it lacks the N-terminal portion of PR. PR78 kDa was able to bind the progestin ligand, indicating that it may have transcriptional activity. In summary, this study has shown that a truncated PR protein, found in breast cancers, is ligand-binding and seems to be derived from PR A, indicating that it may have a role in progesterone signaling, although a deeper understanding of its role, if any, in breast cancer remains to be established.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9467558     DOI: 10.1210/jcem.83.2.4531

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  4 in total

1.  Progesterone signals through membrane progesterone receptors (mPRs) in MDA-MB-468 and mPR-transfected MDA-MB-231 breast cancer cells which lack full-length and N-terminally truncated isoforms of the nuclear progesterone receptor.

Authors:  Yefei Pang; Peter Thomas
Journal:  Steroids       Date:  2011-02-01       Impact factor: 2.668

2.  Altered expression of exon 6 deleted progesterone receptor variant mRNA between normal human breast and breast tumour tissues.

Authors:  E Leygue; H Dotzlaw; P H Watson; L C Murphy
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

3.  The cytoplasmic 60 kDa progesterone receptor isoform predominates in the human amniochorion and placenta at term.

Authors:  Anthony H Taylor; Penny C McParland; David J Taylor; Stephen C Bell
Journal:  Reprod Biol Endocrinol       Date:  2009-03-13       Impact factor: 5.211

Review 4.  Alternative splicing and the progesterone receptor in breast cancer.

Authors:  David M W Cork; Thomas W J Lennard; Alison J Tyson-Capper
Journal:  Breast Cancer Res       Date:  2008-05-30       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.